Patient characteristics and treatment outcome
| Patient . | Age, y/sex . | Line of therapy . | Initial ECOG-PS . | CIRS score* . | IELSG PS . | Ocular involvement . | Induction cycle . | Response to induction . | Response to HCT-ASCT . | Relapse . | Survival, mo . | MMST before therapy . | Last MMST . | Last ECOG-PS . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69/M | First-line | 1 | 10 | 3 | No | 1 | CR | NA | No | 46 | 24 | ND | 1 | NA |
| 2 | 72/M | First-line | 1 | 5 | 1 | No | 2 | CR | CR | No | 45 | 27 | 29 | 0 | NA |
| 3 | 79/F | First-line | 1 | 4 | 2 | No | 2 | CR | CR | No | 40 | 28 | 30 | 1 | NA |
| 4 | 70/M | First-line | 1 | 5 | 1 | No | 2 | PR | CR | No | 38 | 18 | 27 | 1 | NA |
| 5 | 74/F | First-line | 1 | 6 | 2/4† | No | 2 | PR | CR | No | 32 | 28 | 30 | 0 | NA |
| 6 | 78/F | First-line | 1 | 4 | 2 | ND | 2 | PR | CR | No | 47 | 30 | 30 | 1 | NA |
| 7 | 70/F | First-line | 1 | 6 | 3 | No | 2 | PR | uCR | No | 47 | 29 | 30 | 2 | NA |
| 8 | 76/M | First-line | 2 | 4 | 2/4† | ND | 2 | uCR | CR | No | 46 | ND | 30 | 0 | NA |
| 9 | 79/F | First-line | 0 | 4 | 3 | ND | 2 | PR | uCR | No | 36 | 28 | 30 | 0 | NA |
| 10 | 73/M | First-line | 0 | 4 | 3 | No | 2 | PR | uCR | Yes | 19 | 30 | NA | NA | PCNSL |
| 11 | 73/F | First-line | 0 | 5 | 1/4 | No | 2 | PR | PR | No | 31 | ND | 18 | 1 | NA |
| 12 | 71/F | First-line | 2 | 6 | 3 | No | 2 | PR | CR | No | 29 | 23 | 30 | 2 | NA |
| 13 | 73/M | First-line | 2 | 4 | 3/4‡ | No | 2 | PR | PR | No | 26 | 16 | 19 | 2 | NA |
| 14 | 74/F | First-line | 1 | 4 | 3 | No | 2 | PR | uCR | No | 26 | 28 | 28 | 0 | NA |
| Patient . | Age, y/sex . | Line of therapy . | Initial ECOG-PS . | CIRS score* . | IELSG PS . | Ocular involvement . | Induction cycle . | Response to induction . | Response to HCT-ASCT . | Relapse . | Survival, mo . | MMST before therapy . | Last MMST . | Last ECOG-PS . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69/M | First-line | 1 | 10 | 3 | No | 1 | CR | NA | No | 46 | 24 | ND | 1 | NA |
| 2 | 72/M | First-line | 1 | 5 | 1 | No | 2 | CR | CR | No | 45 | 27 | 29 | 0 | NA |
| 3 | 79/F | First-line | 1 | 4 | 2 | No | 2 | CR | CR | No | 40 | 28 | 30 | 1 | NA |
| 4 | 70/M | First-line | 1 | 5 | 1 | No | 2 | PR | CR | No | 38 | 18 | 27 | 1 | NA |
| 5 | 74/F | First-line | 1 | 6 | 2/4† | No | 2 | PR | CR | No | 32 | 28 | 30 | 0 | NA |
| 6 | 78/F | First-line | 1 | 4 | 2 | ND | 2 | PR | CR | No | 47 | 30 | 30 | 1 | NA |
| 7 | 70/F | First-line | 1 | 6 | 3 | No | 2 | PR | uCR | No | 47 | 29 | 30 | 2 | NA |
| 8 | 76/M | First-line | 2 | 4 | 2/4† | ND | 2 | uCR | CR | No | 46 | ND | 30 | 0 | NA |
| 9 | 79/F | First-line | 0 | 4 | 3 | ND | 2 | PR | uCR | No | 36 | 28 | 30 | 0 | NA |
| 10 | 73/M | First-line | 0 | 4 | 3 | No | 2 | PR | uCR | Yes | 19 | 30 | NA | NA | PCNSL |
| 11 | 73/F | First-line | 0 | 5 | 1/4 | No | 2 | PR | PR | No | 31 | ND | 18 | 1 | NA |
| 12 | 71/F | First-line | 2 | 6 | 3 | No | 2 | PR | CR | No | 29 | 23 | 30 | 2 | NA |
| 13 | 73/M | First-line | 2 | 4 | 3/4‡ | No | 2 | PR | PR | No | 26 | 16 | 19 | 2 | NA |
| 14 | 74/F | First-line | 1 | 4 | 3 | No | 2 | PR | uCR | No | 26 | 28 | 28 | 0 | NA |
Overview of patients’ characteristics and treatment outcome of the 14 patients included in the trial. Remission status was assessed according to the International PCNSL Collaborative Group response criteria.
CIRS, Cumulative Illness Rating Scale–Geriatric; F, female; IELSG PS, International Extranodal Lymphoma Study Group Prognostic Score; M, male; MMST, Mini–Mental State Examination; NA, not applicable; ND, not done; PR, partial remission.
Symptoms caused by PCNSL were not considered.
Cerebrospinal fluid protein concentration unknown.
Serum lactate dehydrogenase unknown.